These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 10821643)

  • 21. Remarkable increase in the concentration of 8-hydroxyguanosine in cerebrospinal fluid from patients with Alzheimer's disease.
    Abe T; Tohgi H; Isobe C; Murata T; Sato C
    J Neurosci Res; 2002 Nov; 70(3):447-50. PubMed ID: 12391605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduced CSF PLTP activity in Alzheimer's disease and other neurologic diseases; PLTP induces ApoE secretion in primary human astrocytes in vitro.
    Vuletic S; Peskind ER; Marcovina SM; Quinn JF; Cheung MC; Kennedy H; Kaye JA; Jin LW; Albers JJ
    J Neurosci Res; 2005 May; 80(3):406-13. PubMed ID: 15795933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression.
    Zetterberg H; Skillbäck T; Mattsson N; Trojanowski JQ; Portelius E; Shaw LM; Weiner MW; Blennow K;
    JAMA Neurol; 2016 Jan; 73(1):60-7. PubMed ID: 26524180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nitric oxide synthase is present in the cerebrospinal fluid of patients with active multiple sclerosis and is associated with increases in cerebrospinal fluid protein nitrotyrosine and S-nitrosothiols and with changes in glutathione levels.
    Calabrese V; Scapagnini G; Ravagna A; Bella R; Foresti R; Bates TE; Giuffrida Stella AM; Pennisi G
    J Neurosci Res; 2002 Nov; 70(4):580-7. PubMed ID: 12404512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Age-dependent changes in the glutamate-nitric oxide pathway in the hippocampus of the triple transgenic model of Alzheimer's disease: implications for neurometabolic regulation.
    Dias C; Lourenço CF; Ferreiro E; Barbosa RM; Laranjinha J; Ledo A
    Neurobiol Aging; 2016 Oct; 46():84-95. PubMed ID: 27460153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors.
    Blennow K; Wallin A; Fredman P; Karlsson I; Gottfries CG; Svennerholm L
    Acta Neurol Scand; 1990 Apr; 81(4):323-6. PubMed ID: 2360400
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Age-dependent decline in the apolipoprotein E level in cerebrospinal fluid from control subjects and its increase in cerebrospinal fluid from patients with Alzheimer's disease.
    Fukuyama R; Mizuno T; Mori S; Yanagisawa K; Nakajima K; Fushiki S
    Eur Neurol; 2000; 43(3):161-9. PubMed ID: 10765057
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia.
    Diamandis EP; Scorilas A; Kishi T; Blennow K; Luo LY; Soosaipillai A; Rademaker AW; Sjogren M
    Clin Biochem; 2004 Mar; 37(3):230-7. PubMed ID: 14972646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mass spectrometry and 3-nitrotyrosine: strategies, controversies, and our current perspective.
    Tsikas D; Duncan MW
    Mass Spectrom Rev; 2014; 33(4):237-76. PubMed ID: 24167057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modifications of platelet from Alzheimer disease patients: a possible relation between membrane properties and NO metabolites.
    Vignini A; Nanetti L; Moroni C; Tanase L; Bartolini M; Luzzi S; Provinciali L; Mazzanti L
    Neurobiol Aging; 2007 Jul; 28(7):987-94. PubMed ID: 16815594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer's disease and Parkinson's disease.
    Isobe C; Murata T; Sato C; Terayama Y
    Life Sci; 2005 Aug; 77(15):1836-43. PubMed ID: 15935398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
    Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
    Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differences in cerebrospinal fluid gangliosides between "probable Alzheimer's disease" and normal aging.
    Blennow K; Davidsson P; Wallin A; Fredman P; Gottfries CG; Månsson JE; Svennerholm L
    Aging (Milano); 1992 Dec; 4(4):301-6. PubMed ID: 1294245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subtle Cognitive Impairment and Alzheimer's Disease-Type Pathological Changes in Cerebrospinal Fluid are Common Among Neurologically Healthy Subjects.
    Haapalinna F; Kokki M; Jääskeläinen O; Hallikainen M; Helisalmi S; Koivisto A; Kokki H; Paajanen T; Penttinen J; Pikkarainen M; Rautiainen M; Soininen H; Solje E; Remes AM; Herukka SK
    J Alzheimers Dis; 2018; 62(1):165-174. PubMed ID: 29439329
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer's disease versus normal aging and frontotemporal dementia.
    Simonsen AH; McGuire J; Podust VN; Hagnelius NO; Nilsson TK; Kapaki E; Vassilopoulos D; Waldemar G
    Dement Geriatr Cogn Disord; 2007; 24(6):434-40. PubMed ID: 17971664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential acetylcholine and choline concentrations in the cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia.
    Jia JP; Jia JM; Zhou WD; Xu M; Chu CB; Yan X; Sun YX
    Chin Med J (Engl); 2004 Aug; 117(8):1161-4. PubMed ID: 15361288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease.
    Johansson P; Åberg D; Johansson JO; Mattsson N; Hansson O; Ahrén B; Isgaard J; Åberg ND; Blennow K; Zetterberg H; Wallin A; Svensson J
    Psychoneuroendocrinology; 2013 Sep; 38(9):1729-37. PubMed ID: 23473966
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cerebrospinal Fluid Biomarkers and Reserve Variables as Predictors of Future "Non-Cognitive" Outcomes of Alzheimer's Disease.
    Ingber AP; Hassenstab J; Fagan AM; Benzinger TL; Grant EA; Holtzman DM; Morris JC; Roe CM
    J Alzheimers Dis; 2016; 52(3):1055-64. PubMed ID: 27104893
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased cerebrospinal fluid tau in patients with Alzheimer's disease.
    Jensen M; Basun H; Lannfelt L
    Neurosci Lett; 1995 Feb; 186(2-3):189-91. PubMed ID: 7777193
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhaled nitric oxide reduces tyrosine nitration after lipopolysaccharide instillation into lungs of rats.
    Honda K; Kobayashi H; Hataishi R; Hirano S; Fukuyama N; Nakazawa H; Tomita T
    Am J Respir Crit Care Med; 1999 Aug; 160(2):678-88. PubMed ID: 10430746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.